The DYRK4 Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the DYRK4 gene in the near-haploid HAP1 cell line. This pooled format yields a genetically heterogeneous loss-of-function model, enabling robust and scalable investigation of DYRK4-dependent cellular processes without assuming clonal homogeneity or biallelic inactivation. The knockout is introduced via CRISPR/Cas9-mediated gene disruption, generating a versatile resource for functional genomics, signaling studies, and drug target validation in a human haploid background.
HAP1 cells are a near-haploid human cell line originally derived from the chronic myeloid leukemia cell line KBM-7. Their haploid karyotype makes them uniquely suited for genetic screens and knockout-based functional studies, as disruption of a single allele typically results in a complete loss-of-function phenotype without the confounding effects of a second gene copy. This attribute facilitates the generation of clear and interpretable data in pooled screens, and the cells retain many characteristics of their myeloid lineage, offering a relevant context for cancer biology and kinase signaling research.
DYRK4 is a dual-specificity kinase that phosphorylates serine/threonine and tyrosine residues on key substrates involved in pre-mRNA splicing and cytoskeletal dynamics. It directly phosphorylates and interacts with SF3B1, a core component of the SF3B splicing complex, influencing splice site selection and splicing fidelity. Additionally, DYRK4 phosphorylates the microtubule-associated protein MAP1B and tubulin, thereby regulating microtubule stability and organization. Its activity is modulated by cellular stress signals, and it functions downstream of these cues to coordinate splicing and cytoskeletal responses. Through its effects on microtubule dynamics, DYRK4 is implicated in Hedgehog signaling-dependent ciliogenesis, potentially acting upstream of the transmembrane receptor SMO and modulating GLI transcription factor activity.
In the HAP1 background, disruption of DYRK4 generates an unambiguous loss-of-function context for dissecting its roles in spliceosome assembly and microtubule regulation. The near-haploid state ensures that phenotypes are not masked by residual wild-type alleles, making this polyclonal knockout population an ideal tool for high-throughput functional genomics screens aimed at identifying synthetic lethal interactions or resistance mechanisms. Furthermore, the model supports detailed mechanistic studies of how DYRK4-dependent phosphorylation events govern the balance between splicing fidelity and cytoskeletal dynamics, and how these processes intersect with Hedgehog pathway activity. This is particularly relevant for glioma and ciliopathy research, where DYRK4 signaling aberrations may contribute to pathogenesis.
Researchers can employ these polyclonal knockout cells in a variety of downstream assays, including western blotting to confirm DYRK4 loss, RT-qPCR and RNA-seq for splice variant analysis, immunofluorescence to assess cilia morphology, cell proliferation assays, and flow cytometry for cell cycle profiling. The model is well-suited for investigating kinase inhibitor sensitivity, validating DYRK4 as a drug target, and exploring its role in pre-mRNA splicing regulation. By providing a defined genetic background with targeted DYRK4 disruption, this product accelerates discovery in signal transduction and cancer biology. For further information or to request a quote, please contact Ascent Research.
